Polymorphic Form Control For 5-(Trifluoromethyl)Uracil
Polymorphic Form I vs. Form II: Crystallization Cooling Rates and Anti-Solvent Addition Speed for 5-(Trifluoromethyl)uracil (CAS 54-20-6)
In the synthesis of antiviral prodrugs, the polymorphic form of 5-(Trifluoromethyl)uracil (also known as Trifluorothymine or 5-(Trifluoromethyl)-2,4(1H,3H)-pyrimidinedione) is not merely an academic curiosity—it is a critical quality attribute that directly impacts downstream reactivity and formulation performance. Our field experience with 5-(Trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (CAS 54-20-6) has shown that the two most commonly encountered polymorphs, Form I and Form II, exhibit markedly different dissolution rates and mechanical properties. Form I, typically obtained through rapid cooling (≥5°C/min) from a saturated ethanol/water mixture, tends to form needle-like crystals with a higher aspect ratio. While these needles may filter easily, they often lead to poor flowability and segregation during tablet compression. In contrast, Form II, which is thermodynamically more stable at room temperature, can be reliably produced by controlled slow cooling (0.5–1°C/min) coupled with precise anti-solvent addition. We have observed that adding water as an anti-solvent at a rate of 2–5 mL/min per liter of batch volume, while maintaining the temperature at 50°C, consistently yields compact, equant crystals of Form II. A non-standard parameter we monitor is the viscosity of the mother liquor at the nucleation point; at sub-zero temperatures (e.g., during winter campaigns in unheated warehouses), the viscosity can increase by up to 30%, altering the mass transfer and potentially nucleating a mixed phase. To mitigate this, we recommend pre-heating the anti-solvent to 10–15°C above the batch temperature. For a deeper understanding of how these crystallization parameters tie into the overall synthesis route, refer to our detailed analysis on the optimized synthesis route and impurity profile of 5-(trifluoromethyl)uracil.
Impact of Crystal Habit Variations on Downstream Tablet Compression Hardness and Dissolution Lag Times During Scale-Up
When scaling from gram to kilogram quantities, the crystal habit of 5-(Trifluoromethyl)uracil can introduce significant variability in the manufacturability of the final dosage form. In one scale-up campaign, a batch of Form I needles produced tablets with a hardness of 8–10 kP, while the same compression force on Form II equant crystals yielded 12–14 kP. More critically, the dissolution lag time—the period before 10% of the drug is released—differed by up to 15 minutes between the two habits in a USP Apparatus II test at 50 rpm. This lag is often attributed to the higher surface energy of the needle faces, which can adsorb moisture or excipients more readily. Our team has found that milling Form I to a D90 of <50 µm can partially mitigate the dissolution lag, but this introduces an additional unit operation and potential for amorphous content generation. Therefore, for pharmaceutical intermediate applications, we strongly advocate for direct crystallization of the desired polymorph. The industrial purity of the starting material also plays a role; trace impurities such as 5-chlorouracil (a common byproduct in some manufacturing processes) can act as crystallization inhibitors, promoting Form I. Our COA typically reports this impurity at <0.1% to ensure robust Form II production. For a comprehensive look at impurity control, see our article on the optimized synthesis route and impurity profile of 5-(trifluoromethyl)uracil.
Batch-Specific COA Parameters: Purity Grades, Residual Solvents, and Trace Impurities for Antiviral Prodrug Synthesis
Procurement managers must look beyond the standard assay when sourcing 5-(Trifluoromethyl)uracil for antiviral prodrugs. The following table outlines the key parameters we monitor and report on every batch-specific COA:
| Parameter | Specification (Typical) | Method |
|---|---|---|
| Assay (HPLC) | ≥99.0% | In-house HPLC-UV |
| Water Content (KF) | ≤0.5% | Karl Fischer |
| Residual Solvents (GC) | Ethanol ≤5000 ppm, Water ≤5000 ppm | GC-FID |
| 5-Chlorouracil | ≤0.1% | HPLC |
| Polymorphic Form | Form II (by XRPD) | X-ray Powder Diffraction |
| Melting Point | 245–248°C (dec.) | DSC |
Note: The polymorphic form is not a standard specification for many global manufacturers, but it is essential for consistent prodrug synthesis. We have observed that batches with even 2–3% Form I contamination can reduce the yield of the subsequent silylation step by 5–10% due to slower dissolution kinetics. As a fluorinated building block, this compound's reactivity is highly sensitive to the crystal lattice energy. Please refer to the batch-specific COA for exact values, as slight variations may occur depending on the synthesis route and drying conditions.
Bulk Packaging and Logistics: IBC, 210L Drums, and Handling of Hygroscopic Polymorphs
Both Form I and Form II of 5-(Trifluoromethyl)uracil are slightly hygroscopic, with Form I showing a greater tendency to absorb moisture due to its higher surface area. For bulk shipments, we offer standard packaging in 210L HDPE drums with double LDPE liners, net weight 25 kg or 50 kg. For larger orders, intermediate bulk containers (IBCs) of 500 kg or 1000 kg are available. A field note: during ocean freight, the temperature inside a container can fluctuate, leading to condensation. We have found that including a desiccant bag (e.g., 1 kg of silica gel per drum) and ensuring the drum headspace is nitrogen-blanketed effectively prevents caking and polymorphic transition. Our logistics team can arrange FOB Shanghai or CIF to major ports. We do not claim any specific environmental certifications, but our packaging complies with standard UN recommendations for chemical transport.
Supply Chain Reliability and Drop-in Replacement Strategy for 5-(Trifluoromethyl)uracil in Nucleoside Analogue Production
As a drop-in replacement for existing sources of 5-(Trifluoromethyl)uracil, our product is manufactured to match the identical technical parameters required for nucleoside analogue production. We maintain a safety stock of 5–10 metric tons in our Ningbo warehouse, ensuring supply continuity even during raw material shortages. Our bulk price is competitive, and we offer long-term supply agreements with fixed pricing for 12–24 months. By controlling the polymorphic form from the outset, we eliminate the need for reprocessing at the customer's site, reducing overall cost and lead time. This organic synthesis reagent is a critical starting material for several antiviral prodrugs, and our rigorous quality system ensures batch-to-batch consistency.
Frequently Asked Questions
What cooling ramp protocol do you recommend to consistently obtain Form II?
We recommend a linear cooling ramp from 60°C to 20°C at 0.5°C/min, with anti-solvent (water) addition starting at 50°C at a rate of 3 mL/min per liter. Hold at 20°C for 2 hours before filtration. This protocol has been validated on 100 kg scale.
What is the optimal anti-solvent ratio for Form II crystallization?
A water-to-ethanol ratio of 1:3 (v/v) in the final mixture typically yields pure Form II. However, the addition rate is more critical than the final ratio; slow addition prevents local supersaturation that can nucleate Form I.
How does crystal morphology correlate with downstream processing efficiency?
Equant crystals (Form II) exhibit better flowability (Carr's index <15) and higher bulk density (0.6–0.7 g/mL), leading to more uniform die filling and higher tablet hardness at lower compression forces. Needle-like crystals (Form I) often require pre-milling and can cause sticking during encapsulation.
Can you provide a sample for polymorph screening?
Yes, we can supply 100 g samples of both Form I and Form II for your internal evaluation. Contact our technical team to arrange shipment.
Sourcing and Technical Support
Our team of chemical engineers and quality specialists is ready to support your development and scale-up of antiviral prodrugs. We understand that polymorphic form control is not a one-size-fits-all solution, and we can work with you to tailor the crystallization parameters to your specific process. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.